Literature DB >> 21343576

Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.

Robert A Pazo Cid, Juan Lao, Manuela Lanzuela.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21343576     DOI： 10.1001/jama.2011.159

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Effect of short hairpin RNA of Bcl-xL gene on biological behaviors of HepG-2 cells.

Authors:  Duan Mengxi; Yuan Hong; Wang Nan; Li Shijun; Jiang Yanmei
Journal:  Med Oncol       Date:  2011-04-29       Impact factor: 3.064

2.  The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.

Authors:  Yan Zhou; Yuanliang Zhang; Hanbing Zou; Ning Cai; Xiaojing Chen; Longmei Xu; Xianming Kong; Peifeng Liu
Journal:  Sci Rep       Date:  2015-02-27       Impact factor: 4.379

3.  Facile Fabrication of Reduction-Responsive Supramolecular Nanoassemblies for Co-delivery of Doxorubicin and Sorafenib toward Hepatoma Cells.

Authors:  Qingqing Xiong; Mangmang Cui; Ge Yu; Jian Wang; Tianqiang Song
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.